logo

Mersana Therapeutics, Inc. (MRSN)



Trade MRSN now with
  Date
  Headline
9/17/2020 6:11:32 AM Mersana Therapeutics Reports Updated Interim Data From Ovarian Cancer Cohort Of XMT-1536 Phase 1 Expansion Study
8/31/2020 8:07:07 AM Mersana Therapeutics Appoints Chuck Miller As SVP Of Regulatory Affairs
6/23/2020 10:16:13 AM Stock Alert: Mersana At New High
5/29/2020 12:20:04 AM Mersana Therapeutics Prices Public Offering Of 8 Mln Shares At $19/Shr
4/15/2020 8:18:09 AM Mersana Therapeutics Names Martin Huber To Board
2/28/2020 6:11:11 AM Mersana Therapeutics Q4 Net Loss $16.2 Mln Or $0.34/Shr Vs Loss Of $22.4 Mln Or $0.97/Shr Last Year
8/20/2019 8:07:59 AM Mersana Therapeutics Begins Expansion Study Of XMT-1536 In Patients With Platinum-Resistant Ovarian Cancer And NSCLC
3/8/2019 6:08:36 AM Mersana Therapeutics Q4 Net Loss $22.4 Mln Or $0.97/Shr Vs Loss Of $14.0 Mln Or $0.61/Shr Last Year
3/1/2019 7:09:50 AM Mersana Therapeutics Announces Pricing Of Public Offering Of 21.25 Mln Shares At $4/Shr